Literature DB >> 24445288

Just caring: assessing the ethical and economic costs of personalized medicine.

Leonard M Fleck1.   

Abstract

Personalized medicine has been touted as a revolutionary form of cancer care. It has been portrayed as precision medicine, targeting with deadly accuracy cancer cells and sparing patients the debilitating broad-spectrum side effects of more traditional forms of cancer therapy. But personalized medicine still has its costs to patients and society, both moral and economic costs. How to recognize and address those issues will be the focus of this essay. We start with these questions: Does everyone faced with cancer have a moral right to the most effective cancer care available, no matter what the cost, no matter whether a particular individual has the personal ability to pay for that care or not? Or are there limits to the cancer care that anyone has a right to at social expense? If so, what are those limits and how are those limits to be determined? Are those limits a matter of both morality and economics? I will answer this last question in the affirmative. This is what I refer to as the "Just Caring" problem in health care.
© 2014 Published by Elsevier Inc.

Entities:  

Keywords:  Cancer drugs; Cost-effectiveness; Health care justice; Health care rationing; Personalized medicine; Rational democratic deliberation

Mesh:

Year:  2014        PMID: 24445288     DOI: 10.1016/j.urolonc.2013.09.013

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  9 in total

1.  Making individualized drugs a reality.

Authors:  Huub Schellekens; Mohammed Aldosari; Herre Talsma; Enrico Mastrobattista
Journal:  Nat Biotechnol       Date:  2017-06-05       Impact factor: 54.908

2.  For the Sake of Justice: Should We Prioritize Rare Diseases?

Authors:  Niklas Juth
Journal:  Health Care Anal       Date:  2017-03

3.  Rationing medical education.

Authors:  Kieran Walsh
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

4.  Personalised Medicine and Scarce Resources: A Discussion of Ethical Chances and Challenges from the Perspective of the Capability Approach.

Authors:  Caroline Brall; Peter Schröder-Bäck
Journal:  Public Health Genomics       Date:  2016-06-01       Impact factor: 2.000

Review 5.  Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

Authors:  Qingxin Mu; Jesse Yu; Lisa A McConnachie; John C Kraft; Yu Gao; Gaurav K Gulati; Rodney J Y Ho
Journal:  J Drug Target       Date:  2018-01-10       Impact factor: 5.121

6.  Patient and interest organizations' views on personalized medicine: a qualitative study.

Authors:  Isabelle Budin-Ljøsne; Jennifer R Harris
Journal:  BMC Med Ethics       Date:  2016-05-13       Impact factor: 2.652

Review 7.  Ethical considerations of neuro-oncology trial design in the era of precision medicine.

Authors:  Saksham Gupta; Timothy R Smith; Marike L Broekman
Journal:  J Neurooncol       Date:  2017-05-29       Impact factor: 4.130

8.  Solidarity and cost management: Swiss citizens' reasons for priorities regarding health insurance coverage.

Authors:  Mélinée Schindler; Marion Danis; Susan D Goold; Samia A Hurst
Journal:  Health Expect       Date:  2018-04-14       Impact factor: 3.377

9.  Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective.

Authors:  Peter Brenneisen; Andreas S Reichert
Journal:  Antioxidants (Basel)       Date:  2018-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.